>> haven't looked at Miravant at all but two thoughts about the press release come to mind - the control was a placebo vs. Visudyne and second it doesn't seem they did eye charts to record lines of vision loss or restoration... <<
You are correct on the first point (the Miravant trial was not a head-to-head vs Visudyne); but you are incorrect on the second point –visual acuity (eye chart reading) relative to baseline is the primary efficacy endpoint as the FDA requires. Miravant’s latest PR simply doesn’t talk about visual acuity, and you can draw your own conclusions on the reason for that.
>> I’m curious why this treatment isn't getting more press or as much as Alcon's and DNA's treatment... <<
Miravant’s treatment is not getting a lot of attention from the investment community because it is essentially a Visudyne knockoff. It may take some business away from Visudyne, but that’s about all it will do.
Market Data 
Markets 
AI
